Key Takeaways

• Researchers at the University of Oxford recently shared initial results from the Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial that show dexamethasone can be lifesaving for patients who are severely ill with COVID-19

• Since these results were publicized, Vizient has monitored data from its member hospitals, which include:
  o 610% increase in demand in the week since the initial trial results
  o Aggregated fill rates dropping from 97% to 54% over a six-day period
  o 183% initial spike in demand on the day of announcement

• Dexamethasone is a commonly used corticosteroid used to reduce inflammation in a range of conditions
COVID-19 impact on dexamethasone purchases

610% average increased demand for week ending June 19 compared to week ending June 12

Evaluated:
- Dexamethasone tablet
- Dexamethasone vial for injection

Average fill rate of 97% for week ending June 12
Fill rate drops to 54% for June 19

*Weekend data excluded for visual clarity
Methodology

- Vizient member purchase data was source for all units ordered and filled. Vizient serves more than half of the nation’s hospitals and health systems.

- Eaches ordered was calculated by taking package size x units ordered
  - Example:
    - If 1 package of DEXAMETHASONE SODIUM PHOSPHATE 4mg/mL VIAL 25 X 1 ML VIAL L/F, OUTER, SDV was ordered then 25 VIALS/package x 1 package ordered = 25 eaches ordered.

- Vizient member purchase data was source used to calculate fill rates based upon quantity of eaches sold (supply) divided by quantity of eaches ordered (demand). Fill rate reported on each slide is average for either the month or month to date being evaluated.

- Data from June 15-19, 2020 was compared to baseline data from period June 8-12, 2020.

- The relative percent increase was calculated using the average daily supply and demand for June 8-12, 2020 and for June 15-19, 2020.